Therapeutic promotion of the formation and degradation of PHD2.Fe(III).2OG.HIF2α complexes using small-molecules may be a complementary strategy for treatment of VHL mutant associated renal cell carcinoma (Fig. S15). The gene discussed is EGLN1; the disease is renal cell carcinoma.